IMUX earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Buy, P/E -2.53. Updated 2026-07-23.
Immunic (IMUX) Research Hub
Immunic (IMUX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 11.42 USD (-6.32%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -2.53, market cap 0.15B. This hub links to the full technical, earnings and options research available for IMUX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 11.42 USD (-6.32%) |
| 52-week range | 11.24 USD – 17.43 USD |
| Trend regime | Range |
| 14-day RSI | 34.4 (Bearish) |
| Trailing P/E | -2.53 |
| Market cap | 0.15B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for IMUX
Covered Call on IMUX: how it works, illustrative setup around the real 11.42 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on IMUX: how it works, illustrative setup around the real 11.42 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on IMUX: how it works, illustrative setup around the real 11.42 USD price, max profit/loss, breakeven and when to use it. Educational.
IMUX technical analysis: range, last 11.42 USD, RSI 34.4, 52w range 11.24 USD–17.43 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is IMUX in?
Immunic (IMUX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is IMUX in an uptrend or downtrend?
As of 2026-09-11, IMUX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is IMUX's trailing P/E ratio?
IMUX's trailing P/E is -2.53, with a market cap of 0.15B. See the earnings research page for full valuation detail.
When does IMUX next report earnings?
IMUX is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of -1.17556 USD.